Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals, Inc. - common stock
(NQ:
MIRM
)
95.28
+1.74 (+1.87%)
Delayed Quote
Updated: 1:33 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirum Pharmaceuticals, Inc. - common stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
February 25, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
ACM Research’s AI Surge Collides With Export Controls and Chip Spending Cycles
↗
February 25, 2026
Penn Capital initiated a position in ACM Research, which supplies cleaning and plating tools used in advanced semiconductor manufacturing. As AI-driven chip designs grow more complex, precision...
Via
The Motley Fool
Topics
Artificial Intelligence
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
February 23, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
February 18, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy
↗
February 14, 2026
Via
Chartmill
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup
↗
February 10, 2026
Via
Chartmill
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup
↗
January 01, 2026
Via
Chartmill
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition
↗
February 17, 2026
Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.
Via
The Motley Fool
Topics
Regulatory Compliance
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
↗
February 17, 2026
Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge
↗
February 17, 2026
This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.
Via
The Motley Fool
Topics
Regulatory Compliance
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal'
↗
December 08, 2025
Via
Stocktwits
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
February 05, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Is Mirum Pharmaceuticals on a Strong Path to Profitability?
↗
January 31, 2026
The drugmaker is doing nearly everything else right.
Via
The Motley Fool
Is Mirum Pharmaceuticals About to Soar in 2026?
↗
January 27, 2026
The future looks bright for this high-flying biotech stock.
Via
The Motley Fool
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
January 26, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM)
January 13, 2026
Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage...
Via
PredictStreet
Topics
Economy
Initial Public Offering
3 Top Growth Stocks to Buy in the First Half of 2026
↗
January 13, 2026
Don't wait too long to make a decision on these three stocks.
Via
The Motley Fool
Topics
Artificial Intelligence
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026
↗
January 12, 2026
Focused on rare liver disease therapies, this biopharma company reported a significant insider sale amid strong one-year stock gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
January 12, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right
↗
January 04, 2026
Not all of these predictions may come true. But at least a few of them will likely do so.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now
↗
December 30, 2025
These predictions were easy.
Via
The Motley Fool
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line
↗
December 28, 2025
Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface.
Via
The Motley Fool
Topics
Regulatory Compliance
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
December 19, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
December 08, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026
↗
December 03, 2025
Mirum Pharmaceuticals is a mid-cap biotech stock to keep your eyes on.
Via
The Motley Fool
Topics
Earnings
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?
↗
December 02, 2025
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
